POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma
Replacing one chemotherapy drug in R-CHOP with a CD79b antibody-drug conjugate modestly reduced progression (2-year PFS 76.7% versus 70.2%) without changing survival or side effects.
POLARIX randomised 879 previously untreated patients with diffuse large B-cell lymphoma (IPI 2-5, age 18-80) to pola-R-CHP (polatuzumab vedotin replacing vincristine) or standard R-CHOP for six cycles plus two rituximab doses. The primary endpoint was investigator-assessed PFS. At two years PFS was 76.7% versus 70.2% (hazard ratio 0.73) while overall survival was identical (88.7% versus 88.6%) and the safety profiles were similar. Exploratory subgroups suggested most benefit in activated B-cell-like subtype, older patients and higher IPI, with little or no benefit in germinal-centre subtype. It was the first regimen to beat R-CHOP in two decades of trials.
- 879 untreated DLBCL patients, IPI 2-5; pola-R-CHP vs R-CHOP.
- 2-year PFS 76.7% vs 70.2%; hazard ratio 0.73 (about 6.5 percentage points absolute).
- 2-year overall survival 88.7% vs 88.6%; no difference.
- Grade 3-4 adverse events 57.7% vs 57.5%; peripheral neuropathy rates similar.
- Exploratory: benefit concentrated in ABC subtype, IPI 3-5 and age over 60; GCB subtype showed none.
POLARIX gave the first new first-line standard for DLBCL since rituximab was added to CHOP, and pola-R-CHP is now approved and widely used, especially in higher-risk or ABC-type disease. The gain is modest and survival is unchanged, so many clinicians still use R-CHOP in lower-risk or GCB-type patients. Cost and subgroup uncertainty drive ongoing debate.
- No overall survival benefit; the PFS gain is modest in absolute terms.
- Subgroup effects are exploratory and hypothesis-generating, yet influence practice.
- Excluded very low IPI (0-1) and age over 80.
- High cost relative to a generic-based regimen.